Fibrates: past history or renaissance?
DOI:
https://doi.org/10.15277/bjd.2023.415Keywords:
fibrates, type 2 diabetes, cardiovascular disease, microvascular diseaseAbstract
Fibrates have been in use to modify serum lipids since the 1960s. This review seeks to ascertain their present place in lipid-modifying therapy and prevention of cardiovascular disease, particularly in type 2 diabetes (T2DM).
References
Knopp RH. Drug treatment of lipid disorders. NEnglJMed 1999;341: 498-511. https://doi.org/10.1056/NEJM199908123410707
Troutt JS, Albom WE, Cao G, Konrad RJ. Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. J Lipid Res 2010;51:345-51. https://doi.org/10.1194/jlr.m000620
Belfort R, Berria R, Cornell J, Cusi K. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. JClin EndocrinolMetab 2010;95: 829-36. https://doi.org/10.1210/jc.2009-1487
Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-19. PMID: 8836866.
Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischaemic heart disease and death in men and women. JAMA 2007;298(3): 299-308. https://doi.org/10.1001/jama.2983.299
The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins and risk of vascular disease. JAMA 2009;302(18): 1993-2000. https://doi.org/10.1001/jama.2009.1619
Nordestgaard BC, Varbo A. Triglycerides and cardiovascular disease. Lancet 2014;384:626-35. https://doi.org/10.1016/90140-6736(14)61177-6
Varbo A, Benn M, Tybjaerg-Hansen A, etal. Remnant cholesterol as a causal factor for ischaemic heart disease. J Am Coll Cardiol 2013;61(4):427-36. https://doi.org/10.1016/j.jacc.2012.08.1026
Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9. PMID:7968073
Manninen V, Elo MO, Frick MH, etal. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-51. PMID: 3164788
Bloomfield Rubins H, Robins SJ, Collins D, etal. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341:410-18. https://doi.org/10.1056/NEJM199908053410604
The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-7. https://doi.org/10.1161/01.cir.102.1.21
Frick MH, Syvanne M, Nieminen MS, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997;96:2137-43. https://doi.org/10.1161/01.cir.96.7.2137
Ericsson CG, Hamsten A, Nilsson J, etal. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-53. https://doi.org/10.1016/s0140-6736(96)91343-4
DAIS Investigators. Effects of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-10. PMID:11289345
Elkeles RS, Diamond JR, Poulter C, etal. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St Mary’s, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998;21(4):641-8. https://doi.org/10.2337/diacare.21.4.641
Pyorala K, Pedersen TR, Kjekshus J, etal. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20(4):614-20. https://doi.org/10.2337/diacare.20.4.614
Keech A, Simes RJ, Barter P, et al; The FIELD Study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study: randomised controlled trial. Lancet 2005;366:1849-61. https://doi.org/10.1016/S0140-6736(05)67677-2
The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74. https://doi.org/10.1056/NEJMoa1001282
Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010; 375:1875-84. https://doi.org/10.1016/S0140-6736(10)60656-3
Das Pradhan A, Glynn RJ, Fruchart J-C, et al for the PROMINENT Investigators. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med 2022;387:1923-34. https://doi.org/10.1056/NEJMoa2210645
Park CW, Zhang Y, Zhang X, etal. PPAR alpha agonist fenofibrate improves diabetic nephropathy in db/db mice. KidneyInt 2006;69: 1511-17. https://doi.org/10.1038/sj.ki.5000209
Keech AC, Mitchell P, Summanen PA et al; FIELD Study Investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687-97. https://doi.org/10.S0140=6736(10)61607-9
Chew EY, Ambrosius WT, Davis MD, et al; ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-44. https://doi.org/10.1056/NEJMoa1001288
Preiss D, Spata E, Holman RR, et al. Effect of fenofibrate therapy on laser treatment for diabetic retinopathy: a meta-analysis of randomised controlled trials. DiabetesCare 2022;45:e1-2. https://doi.org/10.2337/dc21-1439
Rajamani K, Colman PG, Ping Li L, et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009;373:1780-8. https://doi.org/10.1016/S0140-6736(09)60698-X
Komuves LG, Hanley K, Lefebvre A-M, etal. Stimulation of PPARα promotes epidermal keratinocyte differentiation in vivo. J Invest Dermatol 2000;115:353-60. https://doi.org/10.1046/j.1523-1747.20 00.00073.x
Published
Issue
Section
License
Publish & Transfer of Copyright Agreement
For the mutual benefit and protection of the Author and the Journal Owner/Publisher it is necessary that the Author provides formal written Consent to Publish and Transfer of Copyright before publication of the Work.
